Health system performance for people with diabetes in 28 low- and middle-income countries: A cross-sectional study of nationally representative surveys.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
03 2019
Historique:
received: 05 09 2018
accepted: 23 01 2019
entrez: 2 3 2019
pubmed: 2 3 2019
medline: 23 10 2019
Statut: epublish

Résumé

The prevalence of diabetes is increasing rapidly in low- and middle-income countries (LMICs), urgently requiring detailed evidence to guide the response of health systems to this epidemic. In an effort to understand at what step in the diabetes care continuum individuals are lost to care, and how this varies between countries and population groups, this study examined health system performance for diabetes among adults in 28 LMICs using a cascade of care approach. We pooled individual participant data from nationally representative surveys done between 2008 and 2016 in 28 LMICs. Diabetes was defined as fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dl), random plasma glucose ≥ 11.1 mmol/l (200 mg/dl), HbA1c ≥ 6.5%, or reporting to be taking medication for diabetes. Stages of the care cascade were as follows: tested, diagnosed, lifestyle advice and/or medication given ("treated"), and controlled (HbA1c < 8.0% or equivalent). We stratified cascades of care by country, geographic region, World Bank income group, and individual-level characteristics (age, sex, educational attainment, household wealth quintile, and body mass index [BMI]). We then used logistic regression models with country-level fixed effects to evaluate predictors of (1) testing, (2) treatment, and (3) control. The final sample included 847,413 adults in 28 LMICs (8 low income, 9 lower-middle income, 11 upper-middle income). Survey sample size ranged from 824 in Guyana to 750,451 in India. The prevalence of diabetes was 8.8% (95% CI: 8.2%-9.5%), and the prevalence of undiagnosed diabetes was 4.8% (95% CI: 4.5%-5.2%). Health system performance for management of diabetes showed large losses to care at the stage of being tested, and low rates of diabetes control. Total unmet need for diabetes care (defined as the sum of those not tested, tested but undiagnosed, diagnosed but untreated, and treated but with diabetes not controlled) was 77.0% (95% CI: 74.9%-78.9%). Performance along the care cascade was significantly better in upper-middle income countries, but across all World Bank income groups, only half of participants with diabetes who were tested achieved diabetes control. Greater age, educational attainment, and BMI were associated with higher odds of being tested, being treated, and achieving control. The limitations of this study included the use of a single glucose measurement to assess diabetes, differences in the approach to wealth measurement across surveys, and variation in the date of the surveys. The study uncovered poor management of diabetes along the care cascade, indicating large unmet need for diabetes care across 28 LMICs. Performance across the care cascade varied by World Bank income group and individual-level characteristics, particularly age, educational attainment, and BMI. This policy-relevant analysis can inform country-specific interventions and offers a baseline by which future progress can be measured.

Sections du résumé

BACKGROUND
The prevalence of diabetes is increasing rapidly in low- and middle-income countries (LMICs), urgently requiring detailed evidence to guide the response of health systems to this epidemic. In an effort to understand at what step in the diabetes care continuum individuals are lost to care, and how this varies between countries and population groups, this study examined health system performance for diabetes among adults in 28 LMICs using a cascade of care approach.
METHODS AND FINDINGS
We pooled individual participant data from nationally representative surveys done between 2008 and 2016 in 28 LMICs. Diabetes was defined as fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dl), random plasma glucose ≥ 11.1 mmol/l (200 mg/dl), HbA1c ≥ 6.5%, or reporting to be taking medication for diabetes. Stages of the care cascade were as follows: tested, diagnosed, lifestyle advice and/or medication given ("treated"), and controlled (HbA1c < 8.0% or equivalent). We stratified cascades of care by country, geographic region, World Bank income group, and individual-level characteristics (age, sex, educational attainment, household wealth quintile, and body mass index [BMI]). We then used logistic regression models with country-level fixed effects to evaluate predictors of (1) testing, (2) treatment, and (3) control. The final sample included 847,413 adults in 28 LMICs (8 low income, 9 lower-middle income, 11 upper-middle income). Survey sample size ranged from 824 in Guyana to 750,451 in India. The prevalence of diabetes was 8.8% (95% CI: 8.2%-9.5%), and the prevalence of undiagnosed diabetes was 4.8% (95% CI: 4.5%-5.2%). Health system performance for management of diabetes showed large losses to care at the stage of being tested, and low rates of diabetes control. Total unmet need for diabetes care (defined as the sum of those not tested, tested but undiagnosed, diagnosed but untreated, and treated but with diabetes not controlled) was 77.0% (95% CI: 74.9%-78.9%). Performance along the care cascade was significantly better in upper-middle income countries, but across all World Bank income groups, only half of participants with diabetes who were tested achieved diabetes control. Greater age, educational attainment, and BMI were associated with higher odds of being tested, being treated, and achieving control. The limitations of this study included the use of a single glucose measurement to assess diabetes, differences in the approach to wealth measurement across surveys, and variation in the date of the surveys.
CONCLUSIONS
The study uncovered poor management of diabetes along the care cascade, indicating large unmet need for diabetes care across 28 LMICs. Performance across the care cascade varied by World Bank income group and individual-level characteristics, particularly age, educational attainment, and BMI. This policy-relevant analysis can inform country-specific interventions and offers a baseline by which future progress can be measured.

Identifiants

pubmed: 30822339
doi: 10.1371/journal.pmed.1002751
pii: PMEDICINE-D-18-03115
pmc: PMC6396901
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1002751

Déclaration de conflit d'intérêts

I have read the journal's policy and the authors of this manuscript have the following competing interests: AS has received research funding from Johnson & Johnson, Inc.

Références

Diabetes Care. 2006 May;29(5):1007-11
pubmed: 16644629
N Z Med J. 2010 Dec 17;123(1327):68-75
pubmed: 21358785
Lancet. 2015 Mar 28;385(9974):1230-47
pubmed: 25458725
Ann Intern Med. 2015 Jun 2;162(11):765-76
pubmed: 25867111
PLoS One. 2015 Aug 05;10(8):e0134834
pubmed: 26244512
Diabetes Care. 2018 May;41(5):1097-1105
pubmed: 29678866
J Glob Health. 2017 Dec;7(2):020407
pubmed: 28959440
Lancet. 2017 Jan 7;389(10064):37-55
pubmed: 27863813
Cardiovasc Diabetol. 2009 Jun 26;8:34
pubmed: 19558646
Lancet. 2012 Nov 17;380(9855):1741-8
pubmed: 23040422
Trop Med Int Health. 2016 Mar;21(3):405-16
pubmed: 26729021
Lancet. 2011 Jul 2;378(9785):31-40
pubmed: 21705069
Lancet Diabetes Endocrinol. 2016 Mar;4(3):197-198
pubmed: 26827114
Lancet Diabetes Endocrinol. 2018 Mar;6(3):208-222
pubmed: 29371076
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
PLoS One. 2017 Oct 2;12(10):e0184264
pubmed: 28968435
Lancet. 2016 Nov 26;388(10060):2665-2712
pubmed: 27671667
Cost Eff Resour Alloc. 2018 Nov 9;16(Suppl 1):49
pubmed: 30455608
Lancet. 2016 Feb 20;387(10020):811-6
pubmed: 26299185
Lancet. 2014 May 31;383(9932):1912-9
pubmed: 24881995
Am J Public Health. 2016 Jan;106(1):74-8
pubmed: 26696288
Curr Opin HIV AIDS. 2016 Jan;11(1):102-8
pubmed: 26545266
PLoS One. 2018 Mar 29;13(3):e0195086
pubmed: 29596495
Cost Eff Resour Alloc. 2018 Nov 9;16(Suppl 1):50
pubmed: 30455609
Clin Chem. 2002 Mar;48(3):436-72
pubmed: 11861436
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
PLoS One. 2013;8(3):e56550
pubmed: 23483887
Lancet Diabetes Endocrinol. 2016 Nov;4(11):903-912
pubmed: 27727123
Lancet Diabetes Endocrinol. 2017 Aug;5(8):622-667
pubmed: 28688818
JAMA Intern Med. 2015 Apr;175(4):596-7
pubmed: 25706538
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Ann Intern Med. 2014 Nov 18;161(10):681-9
pubmed: 25402511

Auteurs

Jennifer Manne-Goehler (J)

Divison of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.

Pascal Geldsetzer (P)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Kokou Agoudavi (K)

Togo Ministry of Health, Lome, Togo.

Glennis Andall-Brereton (G)

Non-Communicable Diseases, Caribbean Public Health Agency, Port of Spain, Trinidad and Tobago.

Krishna K Aryal (KK)

Nepal Health Research Council, Kathmandu, Nepal.

Brice Wilfried Bicaba (BW)

Direction de la Lutte Contre la Maladie, Ministère de la Santé, Ouagadougou, Burkina Faso.

Pascal Bovet (P)

Ministry of Health, Victoria, Seychelles.
Institute of Social and Preventive Medicine, Lausanne, Switzerland.

Garry Brian (G)

The Fred Hollows Foundation NZ, Auckland, New Zealand.

Maria Dorobantu (M)

Cardiology Department, Emergency Hospital of Bucharest, Bucharest, Romania.

Gladwell Gathecha (G)

Division of Non-Communicable Diseases, Kenya Ministry of Health, Nairobi, Kenya.

Mongal Singh Gurung (M)

Health Research and Epidemiology Unit, Ministry of Health, Thimphu, Bhutan.

David Guwatudde (D)

Department of Epidemiology and Biostatistics, School of Public Health, Makerere University, Kampala, Uganda.

Mohamed Msaidie (M)

Comoros Ministry of Health, Solidarity, Social Cohesion and Gender, Moroni, Comoros.

Corine Houehanou (C)

Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.

Dismand Houinato (D)

Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.

Jutta Mari Adelin Jorgensen (JMA)

Partners in Health, Boston, Massachusetts, United States of America.

Gibson B Kagaruki (GB)

National Institute for Medical Research, Dar es Salaam, Tanzania.

Khem B Karki (KB)

Nepal Health Research Council, Kathmandu, Nepal.

Demetre Labadarios (D)

Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.

Joao S Martins (JS)

Faculty of Medicine and Health Sciences, National University of East Timor, Dili, Timor-Leste.

Mary T Mayige (MT)

National Institute for Medical Research, Dar es Salaam, Tanzania.

Roy Wong McClure (RW)

Office of Epidemiology and Surveillance, Caja Costarricense de Seguro Social, San Jose, Costa Rica.

Omar Mwalim (O)

Zanzibar Ministry of Health, Mnazi Mmoja, Zanzibar.

Joseph Kibachio Mwangi (JK)

Division of Non-Communicable Diseases, Kenya Ministry of Health, Nairobi, Kenya.

Bolormaa Norov (B)

National Center for Public Health, Ulaanbaatar, Mongolia.

Sarah Quesnel-Crooks (S)

Non-Communicable Diseases, Caribbean Public Health Agency, Port of Spain, Trinidad and Tobago.

Bahendeka K Silver (BK)

St. Francis Hospital, Kampala, Uganda.

Lela Sturua (L)

Non-Communicable Disease Department, National Center for Disease Control and Public Health, Tbilisi, Georgia.

Lindiwe Tsabedze (L)

Swaziland Ministry of Health, Mbabane, Swaziland.

Chea Stanford Wesseh (CS)

Liberia Ministry of Health, Monrovia, Liberia.

Andrew Stokes (A)

Boston University Center for Global Health and Development, Boston, Massachusetts, United States of America.

Maja Marcus (M)

Department of Economics and Centre for Modern Indian Studies, University of Göttingen, Göttingen, Germany.

Cara Ebert (C)

Department of Economics and Centre for Modern Indian Studies, University of Göttingen, Göttingen, Germany.

Justine I Davies (JI)

MRC/Wits Rural Public Health and Health Transitions Research Unit, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
Institute for Applied Health Research, University of Birmingham, Birmingham, United Kingdom.

Sebastian Vollmer (S)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Department of Economics and Centre for Modern Indian Studies, University of Göttingen, Göttingen, Germany.

Rifat Atun (R)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Till W Bärnighausen (TW)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Africa Health Research Institute, Somkhele, South Africa.
Institute of Public Health, Heidelberg University, Heidelberg, Germany.

Lindsay M Jaacks (LM)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Public Health Foundation of India, New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH